|
| Press Releases |
|
 |
|
| Tuesday, April 16, 2024 |
|
|
SinoMab BioScience preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy |
| SinoMab BioScience announced preclinical results of SM17 on atopic dermatitis (AD) published on International Scientific Journal Allergy. more info >> |
|
| Tuesday, September 12, 2023 |
|
|
SinoMab's IND Application of SM17 has once again Received Approval from NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, August 14, 2023 |
|
|
SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, June 12, 2023 |
|
|
SinoMab Submits another IND Application for SM17 for the Treatment of Atopic Dermatitis, Which was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, May 22, 2023 |
|
|
SinoMab Announces IND Application of SM17 for the Treatment of Asthma was Accepted by NMPA CDE |
| A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases - SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company") more info >> |
|
| Monday, December 19, 2022 |
|
|
SinoMab Awarded the "Most Valuable Pharmaceutical and Medical Company" in the Selection of the "7th Hong Kong Golden Stocks Awards" |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, November 4, 2022 |
|
|
SinoMab Announces Appointment of Mr. Shanchun WANG as the President (China) of the Company |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Wednesday, August 24, 2022 |
|
|
Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
| Friday, July 8, 2022 |
|
|
SinoMab Received the Highest Subsidy from HKSTP |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
| Tuesday, June 21, 2022 |
|
|
The Mechanism of Action of SinoMab's Flagship Product SM03 is Successfully Published in the Journal of Immunology, a Reputable Journal on Immunology in the U.S. |
| SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-listed biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Fourth Star's FSTR Token now Available on CoinMarketCap 
Feb 10, 2025 23:55 HKT/SGT
|
|
|
An Incredible KLAS Triple-Award Win for AGFA HealthCare!
Feb 10, 2025 22:00 HKT/SGT
|
|
|
GTJAI Participated in First Batch of Northbound Bond Connect Offshore RMB Repurchase Business on Launch Day
Feb 10, 2025 18:58 HKT/SGT
|
|
|
Move Digital Leads AI Revolution in 2025, Expands High-Level Consulting for Family Offices Worldwide
Feb 10, 2025 18:00 HKT/SGT
|
|
|
NEC Solution Modernizes Network Infrastructure Construction Work
Feb 10, 2025 15:05 JST
|
|
|
Venturi Partners invests USD 25M in footwear brand JQR
Feb 10, 2025 13:40 HKT/SGT
|
|
|
Renewable Energy Power Purchase Agreements: Analyzing, Structuring, and Negotiating for Bankable Green Investments in Competitive Markets
Feb 10, 2025 13:00 HKT/SGT
|
|
|
Olympus Recognized on CDP's "A List", the Highest Rating in the Field of Climate Change
Feb 10, 2025 11:00 JST
|
|
|
EVCharge Live Thailand 2025 to showcase the future of electric mobility on 26-27 February at BITEC, Bangkok
Feb 10, 2025 09:44 HKT/SGT
|
|
|
foundit Appoints V Suresh as Chief Executive Officer
Feb 10, 2025 09:00 HKT/SGT
|
|
|
Hola Prime Launches Transformative CSR Initiatives to Support Education, Health, and Sustainability
Feb 8, 2025 07:00 HKT/SGT
|
|
|
uSMART Capital, LLC officially approved for U.S. FINRA license
Feb 7, 2025 17:04 HKT/SGT
|
|
|
uSMART Capital, LLC officially approved for U.S. FINRA license
Feb 7, 2025 16:40 HKT/SGT
|
|
|
TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines
Feb 7, 2025 4:00 JST
|
|
|
U.S.-Based Blockchain Kadena and Croatian Football Federation (HNS) Partner to Revolutionize Fan Engagement
Feb 6, 2025 23:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
